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Abstract
Background: Defensins are natural endogenous antimicrobial peptides with potent anti-HIV activity and immuno-
modulatory effects. We recently demonstrated that immature dendritic cells (DC) produce a-defensins1-3 and that a-
defensins1-3 modulate DC generation and maturation. Since DC-HIV interaction plays a critical role during the first steps of
HIV infection, we investigated the possible impact of a-defensins1-3 production by DC on disease progression.
Methodology/Principal Findings: Monocyte-derived DC (MDDC) were analyzed comparatively in healthy controls (HC) and
HIV-infected patients, including untreated ‘‘elite’’ and ‘‘viremic’’ controllers, untreated viremic non-controllers and
antiretroviral-treated patients. We found that production of a-defensins1-3 was significantly increased in MDDC from HIV-
infected patients versus HC, and this increase was mainly due to that observed in controllers, while in non-controllers the
increase was not statistically significant (controllers vs. HC, p,0.005; controllers vs. non-controllers p,0.05). Secreted a-
defensins1-3 by immature MDDC positively correlated with CD4 T cell counts in controllers, but not in non-controllers.
Moreover, independently of their clinical classification, HIV-infected patients with higher a-defensins1-3 secretion by
immature MDDC showed slower disease progression, measured as no decrease in the number of CD4+ T-cells below 350
cell/mm3, lower increase of plasma viral load and no initiation of treatment over time. Plasma alpha-defensins1-3 levels
lacked any relationship with immunologic and virologic parameters.
Conclusions/Significance: High production of a-defensins1-3 by immature DCs appears as a host protective factor against
progression of HIV-1infection, suggesting potential diagnostic, therapeutic and preventive implications. This protective
effect may arise from the activity of a-defensins1-3 to damage the virions prior and/or after their internalization by
immature DC, and hence favoring a more efficient viral processing and presentation to HIV-specific CD4+ T cells, without or
with a minor rate of transmission of infectious HIV-1 virions.
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Introduction
Defensins are natural endogenous antimicrobial peptides with
potent anti-HIV-1 activity [1,2]. According to structural charac-
teristics, two subfamilies of defensins exist in humans, a- and
b-defensins, both with anti-HIV activity[3]. Neutrophils are the
main cellular source for a-defensins1-3, which are also designated
human neutrophil peptides (HNP1-3)[4], although other leukocyte
subsets also produce them[2,5–7]. Apart from their direct anti-
HIV-1 effect[5,8–10], a-defensins1-3 display multiple immunosti-
mulatory activities[11], including chemoattraction of naive T cells
and immature dendritic cells (imDCs)[12], induction of cytokine
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9436
and chemokine production[13–15] and modulation of the expres-
sion of HIV receptors and coreceptors [16].
Recently, we demonstrated that immature (im) monocyte-
derived DC (MDDC) from healthy individuals produce a-
defensins1-3 [17] and that a-defensins1-3 are able to modulate
the maturation and differentiation process of MDDC[18]. MDDC
are a valid and widely used in vitro-generated model of myeloid
DCs [19–23].
Myeloid or classical DC are key cells for the generation and
regulation of the adaptive immune T-cell responses. They are the
most potent professional antigen-presenting cells, unique in their
capacity to induce the antigen-specific activation of naı¨ve CD4
and CD8 T cells in vivo and in vitro, as well as in their ability to
induce the response of CD8 T cells via MHC-class I molecules to
exogenous non-infectious pathogens, a process called cross-
priming or cross-presentation[24–28]. Immature myeloid DCs
are cells specialized in internalizing exogenous components that
reside in the skin, mucosal territories and other non-lymphoid
tissues, where they act as sentinels to detect invading pathogens
and foreign antigens. Once they engulf a pathogen or an antigen
in an inflammatory microenvironment, undergo a process of
maturation and migration to proximal lymphoid tissues, where
they appear as the interdigitating DC in the T-cell areas, and
contact with antigen-specific T cells and induce their activation
[24–28]. Immature myeloid DC such as Langerhans cells in the
mucosal epithelium and interstitial DC in the subepithelial
mucosal tissues are thought to be the first cell types that contact
with HIV-1, which exploits the biology of DCs to spread the
infection to HIV-1-specific and HIV-1-nonspecific CD4 T cells
[29–31]. Nevertheless, DCs are required for induction of T-cell
responses to intracellular pathogens [32], and the capacity of DCs
loaded with infectious and non-infectious HIV-1 virions to activate
naı¨ve HIV-1-specific CD4 and CD8 T cells has been recently
demonstrated in vitro [33]. Therefore, the initial contact of HIV-1
with DCs can result in opposite outcomes, either beneficial in
inducing strong HIV-specific T-cell responses or deleterious in
promoting the spread and dissemination of HIV-1 among HIV-
specific and HIV-nonspecific CD4 T-cells, leading to the pro-
gressive depletion of CD4 T cells that characterize the natural
history of chronic HIV-1 infection. In that setting, given the strong
anti-HIV activity of a-defensins1-3, we hypothesized that a high
production of a-defensins1-3 by immature DC could contribute to
determine a beneficial outcome of the HIV-1-DC interaction
that would involve increased and optimal HIV-1-specific T-cell
responses, which in turn would retard the progression of the
disease. To gain insight about this hypothesis, in vitro generated
immature and mature MDDC were analyzed for their capacity
to produce a-defensins 1-3 comparatively in healthy controls
(HC) and HIV-infected patients, including untreated ‘‘elite’’ and




1. Ethics statement. Patients and control subjects were
recruited at the Hospital Clinic Universitari, Barcelona, after an
informed consent, following the approved rules of the Clinical
Research and Ethics Committee of our Institution. 2. Charac-
teristics. The study included healthy, non-infected controls (HC)
and HIV-1-infected subjects. The HIV-1-infected individuals were
classified as: elite controllers, with plasma viral loads (PVLs) below
50 RNA copies/ml in all the determinations in the absence of
therapy; viremic controllers, with PVLs higher than 50 and lower
than 5000 RNA copies/ml without therapy[34]; viremic non-
controllers, patients with PVLs higher than 5000 RNA copies/ml
without therapy; patients with antiretroviral therapy. All patients
had CD4 T cell counts higher than 450 cell/mm3. The charac-
teristics of the patients are shown in table 1.
Generation of Monocyte-Derived Dendritic Cells (MDDC)
MDDCs were generated from human monocytes as previously
reported[15,17,35,36] from volunteer healthy donors or HIV-1-
infected patients. Briefly, peripheral blood mononuclear cells
(PBMC) were isolated immediately after venous blood extrac-
tion by standard Ficoll density gradient centrifugation, and then
incubated in cell culture dishes for 2 h at 37uC, resuspended at a
concentration of 3 million PBMC per ml in serum-free X-
VIVO15 culture medium (BioWhittaker, Cambrex) supplemented
with 1% of AB human serum. Adherent cells ($95% CD14+)
were washed (3x) in pre-warmed (at 37uC) serum-free X-VIVO10
medium (BioWhittaker, Cambrex), and then differentiated to
immature MDDC in a cell culture for 5 days in a total volume
of 6 ml of complete DC medium, consisting of serum-free X-
VIVO15(BioWhittaker, Cambrex), containing a final concentra-
tion of 1,000 units/ml IL-4 (Strathmann Biotec AG, Hamburg,
Germany) and 1,000 units/ml of GM-CSF (Peprotech, London,
UK). IL-4 and GM-CSF at the same indicated concentration were
added at days 0, 3 and 5. Complete XVIVO-15 medium was also
supplemented with 1% human AB serum, 50 mg/ml gentamycin
(Braun B.) and 2.5 mg/ml fungizone (Bristol-Myers Squibb). To
obtain mature MDDC, a cocktail of proinflammatory cytokines
[17,18], containing IL-1b (10 ng/ml), IL-6 (1000 U/ml) and
TNF-a (1000 U/ml) (Strathmann Biotec AG) was added on day 5,
and the cell culture prolonged for two days. The purity and
immunophenotype of immature and mature MDDC was assessed
by flow cytometry analysis using commercially labeled monoclonal
antibodies (mAbs) against surface markers (See below, ‘‘Flow
Cytometry’’).
Real Time RT-PCR
The expression of a-defensins1-3 mRNA was evaluated by real
time RT-PCR in immature and mature MDDC as previously
Table 1. Characteristics of the patients included in the study.
Characteristic ELITE (n =4) VC (n =15) VNC (n=11) HAART (n=9)
Sex (male/female) 3/1 9/6 11/0 9/0
Geographic origin (Europe/Other) 3/1 12/3 9/2 8/1
Age Mean (min-max) 47.5 (41–63) 37.6 (26–54) 36.2 (28–59) 41.1 (26–56)
CD4 T cell counts (cell/micr) 8036275.6 7416114 5956170 7806225
HIV load (log copies/ml) 1.6960 3.1160.41 4.2360.36 2.4161.11
doi:10.1371/journal.pone.0009436.t001
Alpha-Defensins1-3 and HIV
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described[17]. Total RNA was extracted with Trizol Reagent
(Invitrogen Corporation, Paisley, Scotland), and cDNA gene-
rated as reported. The cDNAs were amplified using LightCycler
FastStart DNA MasterPLUS SYBR Green I kit (Roche, Penzberg,
Germany). Real-time PCR was carried out for 45 cycles using the
LightCycler instrument (Roche) and the specific primers (Sigma-
Aldrich) described previously[17]. PBMC were used as a positive
control[37]. To calculate relative levels of a-defensins1-3 mRNA,
b-2-microglobulin mRNA levels were used as an endogenous
control[36,38] to normalize mRNA quantities. Relative mRNA
levels were calculated using this formula[39]: Relative mRNA
expression = 2 – (Ct of a-defesins 1-3 – Ct of endogenous control)6103. All
cDNA samples were amplified in duplicates.
ELISA
The levels of a-defensins1-3 in cell-free culture supernatants and
plasmas were quantified using the commercial HNP 1-3 ELISA
test Kit (Hycult biotechnology) following the manufacturer in-
structions. The supernatants of immature MDDCs were collected
on day 5 of the cell culture of monocytes in the presence of IL-4
+GM-CSF, before adding the maturation cytokine cocktail. The
supernatants of mature MDDC were collected two days after the
addition of the maturation cocktail.
Flow Cytometry
The immunophenotype of immature and mature MDDCs was
assessed by two-color flow cytometry using FITC- and PE-
conjugated mAbs against CD14, CD80, CD83, CD86, CD11c,
CD40 and HLA-DR (BD Biosciences). Also, CD3, CD19 and
CD56 were used to assess the purity of the cell cultures, resulting
to be lower than 2% of the total population. FITC- and PE-
conjugated isotype-matched monoclonal antibodies of unknown
specificity were used as negative controls.
Intracellular staining of a-defensins 1-3 was performed as
described before with minor modifications [17]. Briefly, immature
MDDCs were pretreated with monensin (Golgi Stop, BD
Biosciences) for 8 h and surface stained with FITC-conjugated
CD40 (BD Biosciences). MDDCs were then fixed and permeabi-
lized with the Cytofix-Cytoperm Plus kit (BD Biosciences) for
20 min, incubated with biotinylated mouse mAb anti-human a-
defensins 1-3 (Clone D21, Hycult Biotechnology, BD Bioscience)
for 30 min and then with PE-conjugated streptavidin (1/1000),
BD Biosciences) during 30 min. The negative control was FITC-
conjugated isotype control (BD Biosciences) and biotin-conjugated
mouse IgG1 isotype control (Southern Biotechnology, Birming-
ham, AL, USA).
The cells were analyzed in a FACScan flow cytometer (Beckton
Dickinson). Data obtained were analyzed with the FlowJo soft-
ware (Tree Star, Inc. Ashland, OR). Expression of surface and
intracellular markers was measured by the percentage of positive
cells and the geometric mean fluorescence intensity.
Statistical Analysis
Data were analyzed using the GraphPad Prism 5.0 software.
The non-parametric tests U-Mann Whitney for the comparison of
two groups or Kruskal-Wallis followed by Dunns post test for the
comparison of more than two groups were used. For the analysis of
the correlation the non-parametric test of Spearman was applied.
The follow-up of patients for the analysis of mortality curves ended
at the month when the event occurred or on April 15, 2009,
whichever occurred first. The differences between the mortality
curves were analyzed with the log-rank test. For all the tests used, a
two sided P value ,0.05 was considered statistically significant.
Results
Increased a-Defensins1-3 Production by MDDC from HIV-
Infected Subjects
To define the levels of a-defensins1-3 produced by immature
and mature MDDC from HIV-negative healthy controls (HC) and
HIV-1-infected patients, we first performed a comparative analysis
of a-defensins1-3 secretion and mRNA relative expression
between HC (n = 15) and HIV-infected patients (n = 39). Secreted
levels in the culture supernatants were assessed by ELISA and
mRNA expression by real time RT-PCR.
The immunophenotype of immature and mature MDDC was
assessed in all individuals. Fig. 1A shows a typical representative
flow cytometry analysis from a HC subject and an HIV-1-infected
patient. As expected from our previous studies[17,18,36,40] with
MDDC from HC, generated in the same conditions as in the
current study, after 5 days of cell culture in the presence of GM-
CSF and IL-4, monocytes had differentiated into immature
MDDCs (imMDDC); these were mostly CD14-negative ($92%)
and virtually all positive ($98%) for HLA-DR and also mostly
positive for CD40, CD11c and CD86, while they lacked expression
of CD80 and CD83, markers of mature DC immunophenotype.
Maturation was induced by two additional days of culture in the
presence of the maturation-cytokine cocktail (Il-1b+IL-6+TNF-a).
In accord with our previous studies mentioned above[17,18,36,40],
the immunophenotype of mature MDDC (mMDDC) was cha-
racterized by an increase in the expression intensity of HLA-DR,
CD40, CD86 and CD11c, and in the expression of CD80 and
CD83 in a notable proportion of cells. The up-regulation of these
markers is a typical feature of DC maturation and was observed in
all the individuals included in the study.
As shown in Fig. 1B and 1C, we found that imMDDCs from
HIV-negative HC produced higher levels of a-defensins1-3 than
mature mMDDCs, in terms of both mRNA relative expression
(Fig. 1B; p,0.02) and levels secreted in the supernatants (Fig. 1C;
p,0.04). In most cases, a-defensins1-3 mRNA levels in mMDDCs
from HC were undetectable or barely detectable. These findings in
HC confirm our previous results with a smaller group of healthy
individuals [17]. In HIV-infected patients, the production of a-
defensins1-3 by imMDDC was also higher than in mMDDC as
measured by both mRNA relative expression (Fig. 1B; p,0.0001)
and secreted levels in the supernatants (Fig. 1C; p,0.005). The
comparison between HC and HIV-infected patients showed that
the production of a-defensins1-3 was significantly higher in HIV-
infected patients than in HC subjects as assessed by both mRNA
expression (fig. 1B; p,0.005) and secreted levels in the super-
natants (fig. 1C; p,0.0001). Among HIV-1-infected patients,
there was a higher number of individuals with detectable levels of
mRNA in mMDDCs compared to HCs, but these levels were
clearly lower than those found in imMDDCs (Fig. 1B, p,0.0001).
Additionally, to confirm that the a-defensins1-3 secreted in the
supernatants were constitutively produced by imMDDCs, intracel-
lular expression of a-defensins1-3 was analyzed by flow cytometry
(Fig. 1D). Immature MDDCs from HCs and HIV-infected patients
were treated with monesin for 8 h to accumulate the a-defensins1-3
inside the cell. Flow cytometry analysis after monensin treat-
ment revealed that 5.362.1% of imMDDC from HCs contained
intracellular a-defensins1-3, an expected finding given our previous
study with healthy individuals [17]. In imMDDC from HIV-
infected patients, the analysis of the intracellular expression of a-
defensins1-3 showed a significant increase in the percentage of
positive cells (2464.8%; figure 1D) as well as in the geometric
mean intensity compared to HCs (P,0.02; figure 1E). This higher
expression of intracellular a-defensins1-3 in imMDDC of HIV-
Alpha-Defensins1-3 and HIV
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Figure 1. Production of a-defensins 1-3 by immature (im) and mature (m) MDDCs. (A) Immature and mature MDDC immunophenotype
from one representative healthy control individual and one HIV-infected subject. X-axis represents HLA-DR expression and Y-axis represents the
surface markers indicated. The percentage of positive cells are shown in each quadrant. (B) Relative expression of a-defensins 1-3 mRNA by real time
RT-PCR in healthy control individuals (n = 15; open circles) and HIV-infected subjects (n = 39; open rhombus). Dots represent each patient and
horizontal lines represent median6 interquartile ranges. Undetectable samples from mMMDC in HC and HIV-infected patients are not represented in
the figure. (C) Levels of a-defensins 1-3 detected in MDDC culture supernatants from healthy non-infected controls (n = 15; white boxes) and HIV-
infected subjects (n = 39; grey boxes). Boxes represent interquartile ranges, horizontal lines inside each box indicate the median and whiskers indicate
maximum and minimum values. (D) Intracellular staining and flow cytometry analysis of a-defensins 1-3 in immature MDDCs. MDDCs were treated
with monensin for 8h and double-stained for CD40 and a-defensins 1-3. CD40 positive cells were selected and the histogram corresponds to positive
cells for intracellular a-defensins 1-3. Histogram represents the isotype control (dots line), healthy control (open line) and HIV-infected subject (filled
histogram). Numbers indicate the percent of positive cells for healthy control (normal number) or HIV-infected patient (bold numbers).
Representative result of four different healthy controls and four HIV-infected patients. (E) Geometric mean fluorescence intensity for intracellular a-
defensins 1-3 in non-infected individuals (n = 4; white box) and HIV-infected subjects (n = 4; grey box). Boxes represent interquartile ranges, horizontal
lines inside each box indicate the median and whiskers indicate maximum and minimum values.
doi:10.1371/journal.pone.0009436.g001
Alpha-Defensins1-3 and HIV
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infected patients compared to HC is in agreement with the higher
levels of RNA expression and a-defensins1-3 secretion.
Since in both HIV-infected patients and HC subjects, imMDDC
were the main a-defensins1-3-producing cells as compared to
mMDDC, all the following analyses were done using imMDDC.
Increased a-Defensins1-3 Production by imMDDC in
Controller versus Non-Controller HIV-Infected Patients
Given the increased production of a-defensins1-3 in the HIV-
infected group, we next analyzed comparatively the different
subgroups of HIV-infected subjects. These subgroups included (i)
‘‘elite controllers’’ with PVL persistently ,50 RNA copies/ml; (ii)
‘‘viremic controllers’’ with PVL between 50 and 5000 RNA
copies/ml; (iii) untreated chronic HIV-infected viremic subjects
with PVL .5000 RNA copies/ml; and (iv) chronic HIV-infected
patients receiving HAART.
The comparison between controllers (elite + ‘‘viremic’’
controllers) and non-controllers (untreated viremic + treated
patients) showed a significantly higher secretion of a-defensins1-
3 by imMDDC from those individuals able to spontaneously
control the infection than in subjects with no control of the
infection (fig. 2A; p,0.05). We also found that the secretion of a-
defensins1-3 in the two controller groups was significantly higher
than in HC subjects. In the non-controller groups this secretion
remained slightly increased compared to HC but without statistical
significance (Fig. 2B).
These data collectively indicate that a-defensins1-3 secretion by
imMDDC is clearly increased in HIV-infected individuals who
spontaneously control the infection.
Secreted Levels of a-Defensins1-3 by imMDDC Correlated
with CD4 T Cell Counts but Not with PVL
We next examined the possible relationship between a-
defensins1-3 secretion by imMDDC and two markers of disease
progression: CD4 T cell count and PVL. For this comparison we
employed CD4 T cell counts and PVL found on the same date of
blood extraction for generation of imMDDC.
In the whole cohort of HIV-infected patients, secreted a-
defensins1-3 by imMDDC did not correlate with CD4 T cell
counts (Fig. 3A). However, a positive correlation was found when
the patients with HAART were eliminated from the analysis
(Fig. 3B; Spearman r = 0.47; p,0.009). In dividing the whole
cohort between controllers and non-controllers, the correlation
was only maintained in controllers (Fig. 3C; Spearman r = 0.58;
p,0.009), but not in non-controllers (Fig. 3D).
No correlation was found between PVL and levels of a-
defensins1-3 secreted by imMDDC (Fig. 4A), even eliminating
untreated patients from the analysis (fig. 4B) or separating
controllers (Fig. 4C) from non-controllers (Fig. 4D).
Plasma Levels of a-Defensins1-3 Showed No Differences
between Controllers and Non-Controllers HIV-Infected
Patients
Given the lack of correlation between secreted a-defensins1-3
by imMDDC and PVL, we wanted to study whether plasma levels
of a-defensins1-3, which are thought to be mainly neutrophil-
derived [41], could show some relationship with immunologic and
virologic parameters.
The plasma levels of a-defensins1-3 were determined using
frozen plasma from 35 patients. No significant differences between
the different groups of HIV-1-infected patients were found in the
plasma levels of a-defensins1-3 (Fig. 5A). It is worth noting the
different profile between plasma a-defensins1-3 levels and the
levels secreted in the supernatant by imMDDC (Fig. 2C).
Figure 2. Levels of a-defensins 1-3 produced by imMDDC from
HIV-infected individuals. (A) Comparison between the secreted
levels of a-defensins 1-3 by imMDDC from HIV-controllers (elite
controllers and viremic controllers; n = 19) and HIV non-controllers
(viremic non-controllers and patients with HAART; n = 20). (B) Secreted
levels of a-defensins 1-3 by imMDDC from healthy non-infected (NI;
n = 15), elite controllers (ELITE; n = 4), viremic controllers (VC; n = 15),
viremic non-controllers (VNC; n = 11) and patients receiving HAART
(HAART; n = 9). Dots indicate each patient and lines represent median6
interquartile ranges.
doi:10.1371/journal.pone.0009436.g002
Figure 3. Positive correlation between secreted levels of a-
defensins 1-3 by imMDDC and CD4 T cell counts. (A) HIV-infected
patients (n = 39), (B) patients not receiving HAART (n = 30), (C)
controllers (elite and viremic controllers; n = 19), and (D) non-controllers
(viremic non-controllers and patients with HAART; n = 20). Spearman
correlation test was applied.
doi:10.1371/journal.pone.0009436.g003
Alpha-Defensins1-3 and HIV
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Furthermore, the analysis of the possible relationship between
plasma levels of a-defensins1-3 and CD4 T cell counts or PVL
lacked any correlation (Fig. 5B and Fig 5C), even after eliminating
the patients with HAART or separating controllers from non-
controllers for the analysis (data not shown).
To test the possible influence of the evolution of the disease in
the levels of a-defensins1-3 in plasma, two samples separated in
time were analyzed for every patient. The results of this analysis
are shown in Fig. 5D. No significant differences were observed
between plasma levels of a-defensins 1-3 in the two different
determinations in patients that remained controllers (Fig. 5D,
white boxes). Similarly, no significant differences were found in
those patients that were controllers in the first determination but
lost viremic control in the second one (Fig. 5D, grey pointed
boxes), controller patients in the first determination with disease
progression and receiving HAART in the second one (Fig. 5D;
grey boxes), and patients receiving HAART during both
determinations (Fig. 5D; grey lined boxes).
These data indicate that the differences found in the levels of a-
defensins1-3 secreted by imMDDC were independent of plasma
levels of these molecules.
Higher Secretion of a-Defensins1-3 by imMDDC from
HIV-Infected Patients Was Associated with Slower
Disease Progression
To analyze the possible association of secreted levels of a-
defensins1-3 by imMDDC from HIV-infected patients with the
risk of disease progression, the untreated patients were separated
in two groups: those with levels of secretion over the median of the
whole group (650 pg/ml) (hereafter ‘‘high secretors’’) and those
with levels below this median value (hereafter ‘‘low secretors’’).
The median was utilized instead of the mean because it is less
influenced by extreme values. Decrease in the number of CD4 T
cells, increase in the PVL, and initiation of treatment were
considered as indicators of disease progression and were analyzed
over time by applying the log-rank test. The percent of patients
with a decrease in the number of CD4 T cells below 350 counts
over time was analyzed. This decrease in the number of CD4 T
cells constitute a critical point to consider treatment according to
current guidelines [42,43]. As shown in fig. 6A, 45% of low a-
defensins1-3-secretor patients suffered this CD4 T-cell decrease,
while it did not occur in the high a-defensins1-3-secretor patients
(p,0.035;HR = 8.9).
In addition, an increase in PVL greater than 0.5 log occurred
in all low a-defensins1-3-secretor patients, versus 65% of high
secretors (fig. 6B; p,0.04; HR = 2.67). Furthermore, 31% of
low secretor patients without treatment at the beginning of the
study initiated HAART during the follow-up, while none of the
high a-defensins1-3-secretors initiated treatment (fig. 6C; p,0.05;
HR = 10).
Taken together these data indicate that those individuals with
higher secretion of a-defensins1-3 by imMDDC had a lower risk of
disease progression.
Discussion
In this study we have investigated the production of a-defen-
sins1-3 by immature DC of HIV-infected patients and their
possible impact on the disease progression rate. As far as we know,
no other studies have approached this issue. Our results revealed
that immature DC from HIV-infected patients produced higher
levels of a-defensins1-3 than the non-infected control group and
these levels were associated with a better control of HIV infection
and slower disease progression.
Although the anti-HIV activity of a-defensins1-3 has been
clearly demonstrated in vitro [5,8–10,15,44], their possible protec-
tive role during HIV infection in vivo remains uncertain. Very few
studies[5,45–50] have analyzed a-defensins1-3 at different ana-
tomical sites in low risk healthy controls and HIV-infected subjects
to try to determine the physiological and pathological levels of
these molecules. For our study we used MDDC, a valid model of in
vivo myeloid DC[20,22,23]. Due to their mucosal localization,
myeloid DC in vivo are thought to be one of the first cells that
encounter the HIV and, after migration to the lymph nodes,
would mediate the transmission of HIV-1 virions to CD4 T cells,
the main source of HIV-1 replication and dissemination [30].
These in vivo myeloid DC might be one of the key cells involved in
early HIV infection, and therefore their capacity to produce and
release a-defensins1-3 by DC may have physiological relevance.
Our HIV-infected patients included controllers and non-con-
trollers to study the behavior of a-defensins1-3 secretion during
opposite situations. The study of controller patients, especially
elite controllers, is of particular relevance since these individuals
demonstrate that natural control of HIV replication in the absence
of antiretroviral therapy is possible[51]. Therefore, the character-
ization of the protective factors that contribute to this con-
troller state will provide valuable information for new therapeutic
approaches.
We found that immature DC from individuals that spontane-
ously control the infection (i.e. elite controllers and ‘‘viremic’’
controllers) produced higher levels of a-defensins1-3 than the non-
controller group (i.e. viremic and treated patients). This higher
production occurred in a constitutive manner, in the absence of
Figure 4. No correlation between secreted levels of a-defensins
1-3 by imMDDC and plasmatic viral load (PVL). (A) HIV-infected
patients (n = 39), (B) patients not receiving HAART (n = 30), (C)
controllers (elite and viremic controllers; n = 19), and (D) non-controllers
(viremic non-controllers and patients with HAART; n = 20). Spearman
correlation test was applied.
doi:10.1371/journal.pone.0009436.g004
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any in vitro stimulation, a characteristic of innate immune
mechanisms[52,53]. Patients with high viremia and patients with
undetectable viremia due to antiretroviral therapy produced
similar levels of a-defensins1-3, indicating that low PVL alone
was not responsible for the increased levels of secreted a-
defensins1-3 in controllers. It is worth noting that all selected
patients were matched to have conserved levels of CD4 T cells, so
the differences observed were not attributable to distinct degrees of
immunodeficiency.
We also found that secreted levels of a-defensins1-3 by
imMDDC positively correlated with CD4 T cell counts, a para-
meter of disease progression. However, this correlation was only
found in untreated patients and especially in the controller group,
but not in non-controllers, even though all selected patients had
similar CD4 T cell counts, providing evidence of a relationship
between higher a-defensins1-3 production by DC and better
immunological state. Interestingly, no correlation was found
between PVL and secreted a-defensins1-3 by MDDC. In agree-
ment with our results, in other studies no correlation was found
between PVL and a-defensins1-3 expression in lymph nodes[48]
or PVL and levels of a-defensins1-3 in breast milk[46].
It should be noted that the analysis of plasma levels of a-
defensins1-3 did not show differences between groups of patients.
High levels of plasma a-defensins1-3 in humans have only been
found during acute infectious processes, such as sepsis, bacterial
meningitis or intrauterine infections [54]. Furthermore, we did not
observe any correlation between plasma levels of a-defensins1-3
and CD4 T cell counts or PVL. This is not contradictory with our
results with MDDC since a-defensins1-3 detected in plasma are
mainly secreted by neutrophils[41]. The possible association
between plasma levels of a-defensins1-3 and neutrophil activation
was not analyzed in our study, but it has been previously found in
pregnant and post-partum women [55]. Furthermore, Baroncelli
et al [45], reported a marked increased in a-defensins1-3 plasma
levels only two weeks after SIV post-infection of macaques, which
coincided with the peak of viral replication, but following the acute
Figure 5. Analysis of plasma levels of a-defensins 1-3. (A) Plasma levels of a-defensins 1-3 detected in the different groups of HIV-infected
patients, elite controllers (ELITE; n = 3), viremic controllers (VC; n = 10), viremic non-controllers (VNC; n = 5) and patients receiving HAART (HAART;
n = 9). Dots indicate each patient and lines represent median6 interquartile ranges. (B) Correlation between CD4 T cell counts and plasma levels of a-
defensins 1-3. (C) Correlation between PVL and plasma levels of a-defensins 1-3. (D) Plasma levels of a-defensins 1-3 in two different determinations
over time in patients that remained controllers (VC-VC; white boxes; n = 13), patients that were controllers in the first determination but lost viremic
control in the second one (VC-VNC; grey pointed boxes; n = 5), controller patients in the first determination with disease progression and HAART in
the second one (VC-ART; grey boxes; n = 8) and patients receiving HAART during both determinations (ART-ART; grey lined boxes; n = 9). Boxes
represent interquartile ranges, horizontal lines inside each box indicate the median and whiskers indicate maximum and minimum values. Mann-
Whitney test was applied for the statistical analysis of every pair and the differences were not significant (NS).
doi:10.1371/journal.pone.0009436.g005
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phase of infection the levels of a-defensins1-3 decreased.
Therefore, it would be conceivable that no differences were found
in the plasma levels of a-defensins1-3 in our chronically-infected
patients.
The results found in the analysis of disease progression markers
over time further support that a higher production of a-defensins1-
3 by immature DC acts as a protective host factor against disease
progression. Indeed, regardless their clinical classification, HIV-1-
infected patients with higher a-defensins1-3 secretion by immature
MDDC showed a delayed disease progression, measured as no
decrease in the number of CD4+ T-cells below 350 cell/mm3,
lower increase in PVL and no initiation of treatment. The
association with a decrease in CD4 T cells below 350 cell/mm3 is
especially relevant since this CD4 T-cell count constitutes a critical
point to decide the starting of treatment[42,43]. The possibility of
a genetic predisposition for a higher production of a-defensins1-3
deserves further studies. In fact, the genes encoding for a-
defensins1-3 map in a cluster on chromosome 8p23.1 and have
been demonstrated to vary in their copy number between
individuals[56–59]. In this line, recent studies reported higher
copy number of the b-defensins HBD-2 and HBD-3 mRNA in
oral mucosa from exposed seronegative (ESN) than healthy
controls [60] and lower copy number of the gene DEFB104 in
HIV-infected than ESN children[61].
In vivo, different immature myeloid DC subsets, such as
Langerhans cells and interstitial DC, are found positioned in
mucosal territories where the natural HIV-1 infection and
dissemination occurs. The production of a-defensins1-3 by these
in vivo myeloid DC subsets has not been investigated, an issue that
deserves further investigation. Even though the levels of a-
defensins1-3 secreted by imMDDC did not reach the described
concentration for direct inactivation of the virus [8], there is the
possibility that the amount of a-defensins1-3 produced by these in
vivo myeloid DC subsets is higher than that produced by our
imMDDC. In this regard, it is worth noting that we have recently
compared directly isolated circulating myeloid DC (CD1c+ CD19-)
and in vitro generated imMDDC of the same donors for secretion of
a-defensins1-3, and we found that the former secreted a 10-fold
higher amount then the latter (M Escribese et al, manuscript in
preparation). On the other hand, it is also plausible that in vivo the
virus would be internalized by immature DC and be localized in
intracellular compartments where the concentration of defensins
might be locally higher than the levels secreted by imMDDC.
Moreover, the reported concentration necessary for direct inacti-
vation of the virus [8] was determined in vitro using CD4 T cells for
the assays. As it is well known, compared to CD4 T cells, immature
myeloid DCs are poorly permissive to HIV-1- replication and
therefore it is likely that the concentration of a-defensins1-3
necessary to inhibit the productive infection of DCs is lower than
the concentration previously reported to be required using CD4 T
cells.
It would be conceivable that a high production of a-defensins1-
3 by immature DC could act by damaging the virus prior or
after its internalization. This would favor a more efficient viral
processing and presentation to CD4+ T cells with a minor
rate of infectious HIV transmission. In addition, a-defensins1-3
have important immunoregulatory properties[2,12,13,15,18], that
might modulate HIV replication and immune cell responses in a
complex manner, influencing the natural history of HIV infection.
Further studies with larger cohorts of HIV-1-infected patients are
required to confirm our observations.
In conclusion, we demonstrate that DC from HIV-infected
patients that spontaneously control the infection produced higher
levels of a-defensins1-3, which positively correlated with CD4 T
cell counts and were associated with slower progression. Our
results open a new line of investigation and future studies will be
needed to determine the possible value of a-defensins1-3 as a
diagnostic or therapeutic tool.
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Figure 6. Levels of a-defensins 1-3 secreted by imMDDC were associated with indicators of disease progression. Patients without
treatment at the moment of blood extraction for the differentiation of MDDC were divided in two groups according to their secreted levels of a-
defensins 1-3 by imMDDC. Levels higher than the median (650 pg/ml) of the whole group of patients (black squares; n = 18) and secreted levels lower
than the median (grey circles; n = 12). (A) Percentage of patients with a decrease in the number of CD4 T cells below 350 cel/mm3 during follow up
time (months). (B) Percentage of patients with an increase in PVL greater than 0.5 logarithms and (C) percentage of patients without HAART at the
moment of determination of a-defensins 1-3 levels but started treatment later during the follow up. P values and hazard ratio (HR) with 95%
confidence interval values are represented in the figure. Log-Rank test was used to determine statistical differences between curves.
doi:10.1371/journal.pone.0009436.g006
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